Albertsons Swings to $481M Q4 Loss on $600M Opioid Settlement Charge; Sales, Guidance Miss
ACI is trading near its 52-week low of $15.8 (6.0% above the low).
Summary
Albertsons reported a significant fourth-quarter loss of $480.8 million, or 94 cents per share, primarily driven by a $600 million charge related to a national opioid settlement framework. While adjusted earnings of 48 cents per share slightly beat analyst expectations, net sales of $20.25 billion and identical sales growth of 0.7% both fell short of Wall Street estimates. Furthermore, the company's fiscal 2026 guidance for identical sales (flat to 1%) and adjusted earnings ($2.22-$2.32 per share) also missed analyst forecasts. This comprehensive earnings report, including the material legal charge and weaker-than-expected outlook, presents a mixed but overall negative picture for the company's financial performance and future prospects. Traders will be closely watching how the market reacts to the significant one-time charge and the cautious guidance.
At the time of this announcement, ACI was trading at $16.75 on NYSE in the Trade & Services sector, with a market capitalization of approximately $8.7B. The 52-week trading range was $15.80 to $22.78. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.